New Feature: Biotech Business Areas

One of the great features of the Biotech-Careers.org website is its biotechnology employer database. In Biotech-Careers.org, biotechnology (biotech) employers are companies and other organizations that are engaged in life sciences research, develop drugs and products, or provide services. Biotech is thus defined broadly to capture the breadth and depth of the industry. This broad definition is also used because students receiving biotech education in community, and other, colleges are learning and developing skills that can be suitable for many kinds of employers. For example, anyone learning to work with and clone DNA could go on to work in organizations that utilize molecular biology in product development, develop DNA-based diagnostics, or provide DNA sequencing services.

Spotlight

Owned Outcomes

Owned Outcomes (O2) is a software company that helps participating organizations win at various forms of value based care including bundled payments. O2 pinpoints opportunities to episode initiators, engages with physicians around key initiatives and supports patients throughout their episodes to a speedy recovery. We are currently helping providers serve patients in 31 states through 7,500+ physicians representing $8bn+ of medical spend. Bundled payments is a team sport. We facilitate data driven decision making and support across the care continuum to provide high quality outcomes, time and time again.

OTHER ARTICLES
MedTech

Better Purification and Recovery in Bioprocessing

Article | September 22, 2022

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More
Medical

Data Analytics: A Groundbreaking Technology in Biotech

Article | July 14, 2022

Biotechnology is a vast discipline of biology that employs diverse biological systems to create solutions that can significantly alter the ways in which they operate across various domains. That said, biotechnology is not a new notion. It has existed for millennia, with ancient civilizations using its earliest incarnations to cultivate crops and create alcoholic beverages. Today, the biotechnology industry has developed by leaps and bounds and has amassed a vast quantity of scientific data through study and research. Given the importance of data in the biotechnology business, it is not difficult to understand why biotech companies utilize data analytics. Modern data analytics tools have made it possible for researchers in the biotech industry to build predictive analytics models and gain knowledge about the most efficient approaches to accomplish their desired goals and objectives. Data analytics is increasingly being adopted by biotech businesses to better understand their industry and foresee any problems down the road. How is Data Analytics Revolutionizing Fields in Biotechnology? Today's business and scientific fields greatly benefit from data. Without the analysis of vast information libraries that provide new insights and enable new innovations, no industry can really advance. Being highly reliant on big data analytics, biotech is not an exception in this regard. With the tools and methods that help scientists systematize their findings and speed up their research for better and safer results, data analytics is making deeper inroads into the biotechnology industry. It is emerging as a crucial link between knowledge and information and is extensively being used for purposes other than just examining the information that is already available. The following are a few of the cutting-edge biotechnology applications of data analytics Genomics and Disease Treatment Pharmaceutical Drug Discovery Drug Recycling and Safety Agriculture and Agri-products Environmental Damage Mitigation Data Analytics Possibilities in Biotechnology With data analytics becoming an integral part of how biotech businesses operate, biotechnologists and related stakeholders need to understand its emergence and crucial role. Data analytics has opened new frontiers in the realm of biotechnology. Thanks to developments in data analytics, research and development activities that once took years may now be accomplished in a matter of months. Also, now scientists have access to biological, social, and environmental insights that can be exploited to create more effective and sustainable products. By understanding the importance of data-related tools and techniques applications, biotech companies are aiming to invest in the popularizing technology to stay updated in the fast-paced biotechnology industry.

Read More
MedTech

Nanostructures: Emerging as Effective Carriers for Drug Delivery

Article | July 11, 2022

Natural remedies have been employed in medicine since antiquity. However, a large number of them fail to go past the clinical trial stages. In vivo instability, poor solubility and bioavailability, a lack of target-specific delivery, poor absorption, and side effects of the medication are only a few of the problems caused by the use of large-sized materials in drug administration. Therefore, adopting novel drug delivery systems with targeted medications may be a solution to address these pressing problems. Nanotechnology has received tremendous attention in recent years and has been demonstrated to help blur the boundaries between the biological and physical sciences. With great success, it plays a vital part in enhanced medication formulations, targeted venues, and controlled drug release and delivery. Limitations of Traditional Delivery Trigger the Adoption of Nanoparticles The field of nanotechnology and the creation of drug formulations based on nanoparticles is one that is expanding and showcasing great potential. It has been thoroughly researched in an effort to develop new methods of diagnosis and treatment and to overcome the limitations of several diseases' current therapies. As a result, nanoparticles are being used to improve the therapeutic effectiveness and boost patient adherence to treatment by increasing medication bioavailability, drug accumulation at a particular spot, and reducing drug adverse effects. The nanoparticles could be transformed into intelligent systems housing therapeutic and imaging agents by manipulating their surface properties, size, correct drug load, and release with targeted drug delivery. Nanostructures facilitate the release of combination medications at the prescribed dose since they remain in the blood circulation system for a long time. Therefore, they result in fewer plasma fluctuations with decreased side effects. Due to their nanoscale, these structures can easily enter the tissue system, promote the absorption of drugs by cells, make medication administration more effective, and ensure that the medicine acts at the targeted location. The Way Ahead Nanomedicine and nano-delivery systems are a comparatively new but fast-evolving science in which nanoscale materials are used as diagnostic tools to deliver drug molecules at precisely targeted sites in a controlled manner. It is finding applications for the treatment of diseases such as cardiovascular, neurodegenerative, cancer, ocular, AIDS, and diabetes, among others. With more research and technological advancement, these drug delivery solutions will open up huge opportunities for companies that work with them.

Read More
MedTech

Next-Gen Gene Therapy to Counter Complex Diseases

Article | July 13, 2022

Gene therapy has historically been used to treat disorders with in-depth knowledge caused by a single genetic mutation. Thanks to the introduction of new generation technologies, the potential of gene therapy is expanding tAo treat diseases that were previously untreatable. Evolution of Gene Therapy One of the major success stories of the twenty-first century has been gene therapy. However, it has not been the same in the past. The field's journey to this point has been long and mostly difficult, with both tragedy and triumph along the way. Initially, genetic disorders were thought to be untreatable and permanently carved into the genomes of individuals unfortunate enough to be born with them. But due to the constant technological advancement and research activities, gene therapy now has the potential to treat various genetic mutation-causing diseases with its ability to insert a new copy and replace faulty genes. Gene Therapy is Finding New Roads in the Medical Sector Gene therapy can help researchers treat a variety of conditions that fall under the general heading of epilepsy, instead of only focusing on a particular kind of disorder brought on by a genetic mutation. Following are some of the domains transformed by gene therapy. Neurology – Gene therapy can be used for the treatment of seizures by directly injecting it into the area causing an uncontrolled electrical disturbance in the brain. Furthermore, by using DNA sequences known as promoters, gene therapy can be restricted to specific neurons within that area. Ophthalmology – Genetic conditions such as blindness can be caused due to the mutation of any gene out of over 200 and resulting in progressive vision loss in children. With advanced gene therapies such as optogenetics, lost photoreceptor function can be transferred to the retinal cells, which are responsible for relaying visual information to the brain. This might give patients the ability to navigate in an unknown environment with a certain level of autonomy. The Future of Gene Therapy The news surrounding gene therapy has been largely favorable over the past few years, with treatment after treatment obtaining regulatory approvals, successful clinical trials, and garnering significant funds to begin development. With more than 1,000 clinical trials presently underway, the long-awaited gene therapy revolution might finally be here.

Read More

Spotlight

Owned Outcomes

Owned Outcomes (O2) is a software company that helps participating organizations win at various forms of value based care including bundled payments. O2 pinpoints opportunities to episode initiators, engages with physicians around key initiatives and supports patients throughout their episodes to a speedy recovery. We are currently helping providers serve patients in 31 states through 7,500+ physicians representing $8bn+ of medical spend. Bundled payments is a team sport. We facilitate data driven decision making and support across the care continuum to provide high quality outcomes, time and time again.

Related News

ASCO: Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing

fiercebiotech | June 03, 2019

CHICAGO-Blueprint Medicines RET inhibitor BLU-667 shrank tumors in 60% of a difficult-to-treat group of lung cancer patients, teeing it up for a 2020 filing in patients with RET-altered non-small cell lung cancer (NSCLC) who had already tried chemotherapy.The phase 2 data, presented Monday at the annual meeting of the American Society of Clinical Oncology (ASCO), show a dramatically better response than is seen with current treatments, Blueprint Chief Medical Officer Andy Boral, M.D., told FierceBiotech.

Read More

In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful

fiercebiotech | June 04, 2019

The $74 billion deal that will see Bristol-Myers Squibb subsume Celgene into its ranks is all but done, but its been a rocky path. Today, Celgene delivered some positive optics for its would-be parent. The Big Biotech and partner Acceleron say that blood disease drug luspatercept, a blockbuster hopeful, has been given a series of FDA passes: First up is a priority review for the erythroid maturation agents potential indication in beta-thalassemia (with an action date of Dec. 4), followed by a PDUFA date of April 4 for its myelodysplastic syndromes (MDS) indication.

Read More

Massive Bio, IBM Watson, others team up with Biden Cancer Initiative for oncology work

fiercebiotech | June 04, 2019

Trial matchmaker Massive Bio, IBM Watson and a host of other organizations have partnered with former Vice President Joe Bidens Cancer Initiative to help improve patients access to and the work coming from cancer studies.This will be done via the so-called Oncology Clinical Trial Information Commons (OCTIC), a shared platform where all information about clinical trials can be stored and accessed for patient matching and other data mining.

Read More

ASCO: Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing

fiercebiotech | June 03, 2019

CHICAGO-Blueprint Medicines RET inhibitor BLU-667 shrank tumors in 60% of a difficult-to-treat group of lung cancer patients, teeing it up for a 2020 filing in patients with RET-altered non-small cell lung cancer (NSCLC) who had already tried chemotherapy.The phase 2 data, presented Monday at the annual meeting of the American Society of Clinical Oncology (ASCO), show a dramatically better response than is seen with current treatments, Blueprint Chief Medical Officer Andy Boral, M.D., told FierceBiotech.

Read More

In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful

fiercebiotech | June 04, 2019

The $74 billion deal that will see Bristol-Myers Squibb subsume Celgene into its ranks is all but done, but its been a rocky path. Today, Celgene delivered some positive optics for its would-be parent. The Big Biotech and partner Acceleron say that blood disease drug luspatercept, a blockbuster hopeful, has been given a series of FDA passes: First up is a priority review for the erythroid maturation agents potential indication in beta-thalassemia (with an action date of Dec. 4), followed by a PDUFA date of April 4 for its myelodysplastic syndromes (MDS) indication.

Read More

Massive Bio, IBM Watson, others team up with Biden Cancer Initiative for oncology work

fiercebiotech | June 04, 2019

Trial matchmaker Massive Bio, IBM Watson and a host of other organizations have partnered with former Vice President Joe Bidens Cancer Initiative to help improve patients access to and the work coming from cancer studies.This will be done via the so-called Oncology Clinical Trial Information Commons (OCTIC), a shared platform where all information about clinical trials can be stored and accessed for patient matching and other data mining.

Read More

Events